PRESS RELEASES<< Back
Chimerix to Participate in Upcoming Investor Conferences
H.C. Wainwright22nd Annual Global Investment Conference: Chimerixwill present a corporate overview on Monday, September 14at 1:00 p.m. ETand participate in investor meetings. Cantor Fitzgerald Virtual Healthcare Conference: Management will participate in investor meetings on Wednesday, September 16.
A live audio webcast of the H.C. Wainwright conference presentation will be available on the Investor Relations section of
DSTAT is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that, compared to commercially available forms of heparin, may be dosed at higher levels without associated bleeding-related complications. DSTAT is being studied in a Phase 2/3 trial to assess safety and efficacy in adults with acute lung injury with underlying COVID-19. A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has been agreed to with the
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
Source: Chimerix, Inc.